Clinical Trial Update: A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating glucodynamic effects of dulaglutide (LY2189265) in Japanese participants with type 2 diabetes has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dulaglutide (dulaglutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED | Results posted: 2019-04-30